-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $74

Benzinga·01/20/2026 14:49:09
Listen to the news
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $70 to $74.